145 related articles for article (PubMed ID: 36400715)
1. Discovery of Potent Inhibitors of Cyclin-Dependent Kinases 7 and 9: Design, Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.
Chen R; Hassankhani R; Long Y; Basnet SKC; Teo T; Yang Y; Mekonnen L; Yu M; Wang S
ChemMedChem; 2023 Feb; 18(3):e202200582. PubMed ID: 36400715
[TBL] [Abstract][Full Text] [Related]
2. Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.
Tadesse S; Yu M; Mekonnen LB; Lam F; Islam S; Tomusange K; Rahaman MH; Noll B; Basnet SK; Teo T; Albrecht H; Milne R; Wang S
J Med Chem; 2017 Mar; 60(5):1892-1915. PubMed ID: 28156111
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy.
Zeng WB; Ji TY; Zhang YT; Ma YF; Li R; You WW; Zhao PL
Bioorg Chem; 2024 Feb; 143():107019. PubMed ID: 38096683
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
[TBL] [Abstract][Full Text] [Related]
7. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
[TBL] [Abstract][Full Text] [Related]
8. Discovery of
Fanta BS; Lenjisa J; Teo T; Kou L; Mekonnen L; Yang Y; Basnet SKC; Hassankhani R; Sykes MJ; Yu M; Wang S
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049714
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
10. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83.
Liu X; Lam F; Shi S; Fischer PM; Wang S
Invest New Drugs; 2012 Jun; 30(3):889-97. PubMed ID: 21331744
[TBL] [Abstract][Full Text] [Related]
11. 3,5,7-Substituted Pyrazolo[4,3-
Jorda R; Havlíček L; Peřina M; Vojáčková V; Pospíšil T; Djukic S; Škerlová J; Grúz J; Renešová N; Klener P; Řezáčová P; Strnad M; Kryštof V
J Med Chem; 2022 Jul; 65(13):8881-8896. PubMed ID: 35749742
[TBL] [Abstract][Full Text] [Related]
12. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
13. Discovery of
Huang J; Wang X; Dong R; Liu X; Li H; Zhang T; Xu J; Liu C; Zhang Y; Hou S; Tang W; Lu T; Chen Y
J Med Chem; 2021 Sep; 64(17):12548-12571. PubMed ID: 34415148
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents.
Lukasik PM; Elabar S; Lam F; Shao H; Liu X; Abbas AY; Wang S
Eur J Med Chem; 2012 Nov; 57():311-22. PubMed ID: 23085105
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of 4-styrylpyrazoles and Evaluation of their Inhibitory Effects on Cyclin-dependent Kinases.
Toman D; Jorda R; Ajani H; Kryštof V; Cankař P
Med Chem; 2022; 18(4):484-496. PubMed ID: 34365958
[TBL] [Abstract][Full Text] [Related]
16. Ligand- and structure-based pharmacophore modeling, docking study reveals 2-[[4-[6-(isopropylamino) pyrimidin-4-yl]-1H-pyrrolo[2,3-b] pyridin-6-yl] amino] ethanol as a potential anticancer agent of CDK9/cyclin T1 kinase.
Hussain A; Verma CK
J Cancer Res Ther; 2019; 15(5):1131-1140. PubMed ID: 31603123
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
[TBL] [Abstract][Full Text] [Related]
19. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
